Summary
This Form 8-K filing from Abbott Laboratories, dated April 15, 2009, announces the company's financial results for the first quarter of 2009. The report primarily focuses on the release of their earnings, highlighting the use of non-GAAP financial measures alongside GAAP. These non-GAAP measures, which exclude specified items like acquisition-related costs, cost reduction initiatives, and litigation settlements, are presented to offer investors a clearer view of ongoing business performance. Abbott's management emphasizes that these adjusted figures are intended to provide useful insights into the company's operational performance and are used internally for monitoring. However, the company cautions investors to consider these non-GAAP measures in conjunction with, and not as a replacement for, their standard GAAP financial statements, ensuring a comprehensive understanding of the company's financial health.
Key Highlights
- 1Abbott Laboratories announced its first-quarter 2009 financial results on April 15, 2009.
- 2The company utilized non-GAAP financial measures in its earnings announcement.
- 3Non-GAAP measures exclude specified items such as acquisition-related costs, cost reduction initiatives, litigation settlements, product launch costs, acquired in-process R&D, and certain investment gains/losses.
- 4Abbott's management believes these non-GAAP measures provide useful information for evaluating ongoing business performance.
- 5These adjusted figures are also used internally by management to monitor business performance.
- 6Investors are cautioned to consider non-GAAP measures in addition to, and not as a substitute for, GAAP measures.